---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-035271"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2022-10-26T23:59:59+00:00"
generated_at: "2026-06-23T00:50:36.430622+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Viking Therapeutics Q3 net loss $15.8M ($0.21/sh); cash $155M; three clinical data reads in 2023

## Summary
- Net loss of $15.8M ($0.21 per share) vs $13.2M ($0.17) in Q3 2021; nine-month net loss $49.3M ($0.64) vs $42.6M ($0.55).
- Cash, cash equivalents and short-term investments $155M, down from $202M at year-end 2021.
- VK2809 VOYAGE Phase 2b for NASH/fibrosis enrollment to finish Q4 2022; primary endpoint data 1H 2023.
- Phase 1 data for dual GLP-1/GIP agonist VK2735 expected early 2023; Phase 1b VK0214 for X-ALD data in 1H 2023.
- R&D expense $12.0M in Q3 vs $10.8M a year ago; G&A $4.2M vs $2.6M.

## SEC filing metadata
- accession: 0001564590-22-035271
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2022-10-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000156459022035271/0001564590-22-035271-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000156459022035271/vktx-8k_20221026.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-035271
- JSON: https://secwatch.observer/filing/0001564590-22-035271.json
- Plain text: https://secwatch.observer/filing/0001564590-22-035271.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.